Supplemental Evidence and Data Request on Treatments for Acute Pain: A Systematic Review
| Published date | 08 January 2020 |
| Citation | 85 FR 904 |
| Record Number | 2020-00104 |
| Section | Notices |
| Court | Agency For Healthcare Research And Quality |
Federal Register, Volume 85 Issue 5 (Wednesday, January 8, 2020)
[Federal Register Volume 85, Number 5 (Wednesday, January 8, 2020)]
[Notices]
[Pages 904-906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-00104]
[[Page 904]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Treatments for Acute
Pain: A Systematic Review
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for Supplemental Evidence and Data Submissions.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Treatments for
Acute Pain: A Systematic Review, which is currently being conducted by
the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to
published and unpublished pertinent scientific information will improve
the quality of this review.
DATES: Submission Deadline on or before 30 days after date of
publication of this Notice.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality, ATTN: EPC SEADs
Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Jenae Benns, Telephone: 301-427-1496
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Treatments for Acute
Pain: A Systematic Review. AHRQ is conducting this systematic review
pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C.
299a(a).
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Treatments for Acute Pain: A Systematic Review,
including those that describe adverse events. The entire research
protocol is available online at: https://effectivehealthcare.ahrq.gov/products/treatments-acute-pain/protocol.
This is to notify the public that the EPC Program would find the
following information on Treatments for Acute Pain: A Systematic Review
helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this indication. In the list, please indicate whether
results are available on ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements: Study
number, study period, design, methodology, indication and diagnosis,
proper use instructions, inclusion and exclusion criteria, primary and
secondary outcomes, baseline characteristics, number of patients
screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including a study number, the study period,
design, methodology, indication and diagnosis, proper use instructions,
inclusion and exclusion criteria, and primary and secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this indication and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on indications not
included in the review cannot be used by the EPC Program. This is a
voluntary request for information, and all costs for complying with
this request must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The systematic review will answer the following questions. This
information is provided as background. AHRQ is not requesting that the
public provide answers to these questions.
Key Questions (KQ)
Each Key Question (KQ) focuses on a specific acute pain condition.
The conditions and related subquestions are listed below:
KQ1: Acute back pain (including back pain with radiculopathy)
KQ2: Acute neck pain (including neck pain with radiculopathy)
KQ3: Musculoskeletal pain not otherwise included in KQ1 or KQ2
(including fractures)
KQ4: Peripheral neuropathic pain (related to herpes zoster and
trigeminal neuralgia)
KQ5: Postoperative pain after discharge
KQ6: Dental pain (surgical and nonsurgical after discharge)
KQ7: Kidney stones
KQ8: Sickle cell crisis (episodic pain)
For each condition above, the following subquestions will be
addressed:
Opioid Therapy
a. What is the comparative effectiveness of opioid therapy versus:
(1) Nonopioidpharmacologic therapy (e.g., acetaminophen, nonsteroidal
anti-inflammatory drugs [NSAIDs], antidepressants, anticonvulsants) or
(2) nonpharmacologic therapy (e.g., exercise, cognitive behavioral
therapy, acupuncture) for outcomes related to pain, function, pain
relief satisfaction, and quality of life and after followup at the
following intervals: Less than 1 day; 1 day to less than 1 week; 1 week
to less than 2 weeks; 2 weeks to less than 4 weeks; 4 weeks or longer?
b. How does effectiveness of opioid therapy vary depending on: (1)
Patient demographics (e.g. age, race, ethnicity, gender); (2) patient
medical or psychiatric comorbidities; (3) dose of opioids; (4) duration
of opioid therapy, including number of opioid prescription refills and
quantity of pills used; (5) opioid use history; (6) substance use
history; (7) use of concomitant therapies?
c. What are the harms of opioid therapy versus nonopioid
pharmacologic therapy, or nonpharmacologic therapy with respect to: (1)
misuse, opioid use disorder, and related outcomes; (2) overdose; (3)
other harms including gastrointestinal-related harms, falls, fractures,
motor vehicle accidents, endocrinological harms, infections,
cardiovascular events, cognitive harms, and psychological harms (e.g.,
depression)?
[[Page 905]]
d. How do harms vary depending on: (1) Patient demographics (e.g.,
age, gender); (2) patient medical or psychiatric comorbidities; (3) the
dose of opioid used; (4) the duration of opioid therapy; (5) opioid use
history; or (6) substance use history?
e. What are the effects of prescribing opioid therapy versus not
prescribing opioid therapy for acute pain on (1) short-term (65 years.
[ssquf] Patients with history of
substance use disorder.
[ssquf] Patients currently under
treatment for opioid use disorder with
opioid agonist therapy or naltrexone.
[ssquf] Patients with a history of
psychiatric illness.
[ssquf] Patients with history of
overdose.
[ssquf] Pregnant/breastfeeding women.
[ssquf] Patients with comorbidities
(e.g., kidney disease, sleep disordered
breathing).
Interventions................ Opioid therapy:
a-e. Any systemic opioid, including
agonists, partial agonists, and mixed
mechanism opioids.
f. Instruments, genetic/metabolic tests
for predicting risk of misuse, opioid
use disorder, and overdose.
g. Use of risk prediction instruments,
genetic/metabolic tests.
h. The following factors: (1) Existing
opioid management plans; (2) patient
education; (3) clinician and patient
values and preferences related to
opioids; (4) urine drug screening; (5)
use of prescription drug monitoring
program data; (6) availability of close
followup.
Nonopioid therapy: Oral, parenteral, or
topical nonopioid pharmacological
therapy used for acute pain
(acetaminophen, nonsteroidal anti-
inflammatory drugs, skeletal muscle
relaxants, benzodiazepines,
antidepressants, anticonvulsants,
cannabis).
[[Page 906]]
Noninvasive nonpharmacological therapy:
Noninvasive nonpharmacological therapies
used for acute pain (exercise [and
related therapies], cognitive behavioral
therapy, meditation, relaxation, music
therapy, virtual reality, acupuncture,
massage, manipulation/mobilization,
physical modalities [transcutaneous
electrical nerve stimulation,
ultrasound, braces, traction, heat,
cold]).
Comparators.................. Opioid therapy:
a-d. Usual care, another opioid,
nonopioid drug, or noninvasive,
nonpharmacological therapy.
e. Usual care, another opioid, nonopioid
drug, or noninvasive, nonpharmacological
therapy, no opioid/nothing prescribed.
f. Reference standard for misuse, opioid
use disorder, or overdose; or other
benchmarks.
g. Usual care.
h. Not utilizing the factors specified in
interventions (h) above.
Nonopioid pharmacological therapy:
Other nonopioid pharmacological therapy
or noninvasive nonpharmacological
therapy.
Noninvasive nonpharmacological therapy:
Sham treatment, waitlist, usual care,
attention control, and no treatment; or
other noninvasive nonpharmacological
therapy.
Outcomes..................... Opioid therapy:
a-d, g, i. Pain, function, pain relief
satisfaction, and quality of life,
harms, adverse events (including
withdrawal, risk of misuse, opioid,
opioid use disorder, overdose).
e. Persistent opioid use.
f. Measures of diagnostic accuracy.
h. Opioid prescribing rates.
Nonopioid therapy: Pain, function, pain
relief satisfaction, quality of life and
quality of life, harms, adverse events,
opioid use.
Noninvasive nonpharmacological therapy:
Pain, function, pain relief
satisfaction, quality of life and
quality of life, harms, adverse events,
opioid use.
Time of followup............. =4 weeks.
Setting...................... Emergency department (initiation of
therapy and following discharge),
physician's office, outpatient or
inpatient surgical center, dental clinic
or oral surgery center, inpatient
(sickle cell only).
Study design................. All KQs: RCTs; in addition:
e. Cohort studies (for long-term opioid
use).
f. studies assessing diagnostic accuracy.
h. cohort studies and before-after
studies assessing effects on prescribing
rates.
------------------------------------------------------------------------
Abbreviations: RCT = randomized controlled trial.
Dated: January 3, 2020.
Virginia Mackay-Smith,
Associate Director, Office of the Director, AHRQ.
[FR Doc. 2020-00104 Filed 1-7-20; 8:45 am]
BILLING CODE 4160-90-P
